Abstract:Background: Lacosamide (LCM) is a newer anti-seizure medication (ASM) that was approved in China in 2018, but its real-world clinical data and plasma concentrations in Chinese children with epilepsy are very limited. Of note, the reference range for routine LCM therapeutic drug monitoring is still unknown. The purpose of this study was to investigate the efficacy and safety of LCM as a monotherapy or an adjunctive treatment with other ASMs and to evaluate the potential factors affecting its efficacy and variable LCM plasma concentrations in Chinese children with epilepsy. Methods: Children with epilepsy (<18 years) with routine plasma LCM monitoring from March 2019 to December 2021 at the Department of Pharmacy, Children's Hospital of Nanjing Medical University were retrospectively collected. Clinical data were obtained from the hospital information system. Results: 76 pediatric patients (52 males) were finally enrolled. Mean age was 7.9 years (1.3–17.3 years) with a mean dose of LCM 6.3 mg/kg/day (2.0–11.3 mg/kg/day). The TDM data as a whole showed that the median plasma trough concentration ( C 0 ) was 3.42 μg/mL (1.25–8.31 μg/mL). A 6-month LCM add-on therapy produced 70% of patients achieving ≥50% seizure frequency reductions, and the number was 81% for the one-year follow-up findings. Interestingly, more patients who took LCM monotherapy achieved seizure freedom over the same periods of follow-up observations. Under maintenance dosages, approximately 92.1% of the C 0 values were 2.0–7.0 μg/mL. The plasma- C 0 -to-daily dose ( C 0 /Dose) ratio was significantly associated with age and body weight (BW). The C 0 /Dose ratio in patients aged 1– ≤ 6 and 6– ≤ 12 years was significantly higher by 81% and 29% than those aged 12– ≤ 18 years, respectively. The C 0 /Dose ratio in patients with a BW of ≥40 kg was 1.7-fold lower than in patients with a BW of ≤ 20 kg. In addition, complex LCM-ASMs interactions were observed. Oxcarbazepine significantly decreased the C 0 /Dose ratio of LCM by 28%. Conclusion: This retrospective study confirmed the effectiveness and tolerability of the LCM treatment used alone or with other ASMs in children with focal epilepsy. Children with higher BW and older age have lower C 0 /Dose ratio. Complex drug interactions between LCM and other concomitant ASMs were revealed. Notably, based on the data in our hands, the reference range, i.e ., 2.0–7.0 μg/mL, for routine LCM monitoring may be feasible. The real-world evidence of this study supports LCM as a promising option in children with focal epilepsy.

Blood levels monitoring of antiepileptic drug in epileptic children with "pure Chinese medicine"

Trends of Anti-Seizure Medication Use in Pediatric Patients in Six Cities in China from 2013 to 2018

Initial Therapeutic Target Attainment of Perampanel in Pediatric Patients with Epilepsy

Anti-seizure Medication Prescription in Adult Outpatients with Epilepsy in China, 2013–2018

Investigation of so-called antiepileptic "traditional Chinese medicine mixture'' added with western drugs in secret

Simultaneous monitoring of seven antiepileptic drugs by dried blood spot and dried plasma spot sampling: method validation and clinical application of a LC–MS/MS-based technique

Monitoring of the content of phenobarbital and dilantin in blood

Plasma lacosamide monitoring in children with epilepsy: Focus on reference therapeutic range and influencing factors

Pharmaceutical care for a child with epilepsy by clinical pharmacists

An LC-ESI-MS/MS assay for the therapeutic drug monitoring of 15 antiseizure medications in plasma of children with epilepsy

Therapeutic drug monitoring of free perampanel concentrations in practice: A practical analytical technique based on centrifugal ultrafiltration sample separation

Therapeutic Drug Monitoring of 6 New-Generation Antiseizure Medications Using a Mass Spectrometry Method: Analysis of 2-Year Experience in a Large Cohort of Korean Epilepsy Patients

Double-blind Crossover Controlled Study on Antiepilepsirine.

Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update

Off-label Oral-Antiepileptic Drugs Use in Inpatients of a Tertiary Pediatric Epileptic Center in China: a Cross Sectional Study

Advances in the individualized treatment of novel antiepileptic drugs for children

Outcomes Of Sustained-Release Formulation Of Valproate And Topiramate Monotherapy In Patients With Epilepsy: A Multi-Centre, Cohort Study

Analysis of Monitoring of 375 Cases in Clinical Value of Therapeutic Drugs

An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs

Therapeutic Drug Monitoring of Antiepileptic Drugs at a Tertiary Care Hospital of Eastern Nepal

Setting up population pharmacokinetics/pharmacodynamics model of VPA in children with epilepsy by NONMEM software